10-Q/A: America Great Health Files Amended Quarterly Report Amidst Ongoing Financial Challenges

America Great Health has filed an amended quarterly report on Form 10-Q/A for the period ended September 30, 2023, to include updated certifications and explanations regarding its financial results.

Summary

• America Great Health filed an amendment to its quarterly report for the period ending September 30, 2023, to include updated certifications and explanations.
• The company's sales decreased significantly to $13,808 from $51,938 compared to the same period last year, due to unstable production of new nutrition supplements.
• Cost of goods sold also decreased to $177 from $27,500, as production was still in laboratory trials.
• Gross profit decreased to $13,631 from $24,428, primarily due to the decline in sales.
• Operating expenses decreased to $88,569 from $152,659, mainly due to reduced management fees and OID expenses.
• The net loss decreased to $156,980 from $192,754, primarily due to the decrease in sales.
• The company's cash balance was $54,626 as of September 30, 2023, and they have a shareholders' deficit of $4,680,038.
• The company's ability to continue as a going concern is dependent on securing additional capital and achieving profitable operations.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including declining sales, substantial losses, and a going concern issue, indicating a negative outlook for the company.

Positives

• The net loss decreased to $156,980 from $192,754 compared to the same quarter last year.
• Operating expenses decreased to $88,569 from $152,659 year-over-year.

Negatives

• Sales decreased significantly to $13,808 from $51,938 compared to the same quarter last year.
• The company has a shareholders' deficit of $4,680,038.
• The company's new nutrition supplements are still in small-scale laboratory trials, impacting sales and cost of goods sold.
• The company's ability to continue as a going concern is in doubt.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital and achieving profitable operations.
• The company has incurred recurring net losses and has a significant shareholders' deficit.
• The unstable production of new nutrition supplements is impacting sales and profitability.
• The company lacks a functioning audit committee and has material weaknesses in internal controls.

Future Outlook

The company's future is dependent on securing additional capital and achieving profitable operations, with no assurance of success in either.

Management Comments

• Management believes that the material weaknesses set forth in above did not have an effect on our financial results.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the healthcare and biotechnology sector, focusing on innovative technologies and product development. The challenges faced by the company, such as unstable production and financial losses, are not uncommon in early-stage biotech companies.

Comparison to Industry Standards

• The company's revenue of $13,808 for the quarter is significantly lower than many comparable companies in the health and nutrition sector, which often report revenues in the millions.
• The company's net loss of $156,980, while an improvement year-over-year, is still substantial for a company of its size and indicates significant challenges in achieving profitability.
• The company's negative working capital of $3,337,845 and accumulated deficit of $4,680,038 are concerning and suggest a high level of financial risk compared to industry benchmarks.
• The lack of a functioning audit committee and material weaknesses in internal controls are significant issues that need to be addressed to meet industry standards for corporate governance.
• Compared to companies like GNC or Herbalife, which have established supply chains and distribution networks, America Great Health is still in the early stages of product development and commercialization.

Corporate Governance

Legal Proceedings

• The company is not currently involved in any legal proceedings.

Related Party Transactions

• During the three months ended September 30, 2023, the company's current majority shareholder advanced $77,470 to the company as working capital and the company repaid $18,364 to the shareholder.
• As of September 30, 2023, the company owed its current majority shareholder $484,248.

Stakeholder Impact

• Shareholders are at risk due to the company's financial instability and going concern issues.
• Employees may face uncertainty due to the company's financial challenges.
• Customers may experience delays or disruptions in product availability due to production issues.
• Suppliers and creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company needs to secure additional capital to continue operations.
• The company needs to improve the production and commercialization of its new nutrition supplements.
• The company needs to address the material weaknesses in internal controls and establish a functioning audit committee.

Key Dates

Keywords

financial results, quarterly report, amendment, going concern, net loss, sales, operating expenses, shareholders deficit, internal controls, nutrition supplements